January 27, 2023
The FDA wants clinicians to avoid using the neutralizing antibody as it appears to be less effective against newer circulating strains of the SARS-CoV-2 virus.
August 23, 2022
Pfizer-BioNTech filed with the FDA for emergency use authorization of a 30-mcg dose of an Omicron BA.4.BA.5-adapted vaccine for those aged ≥12 years.